Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
Authors: Yasuo Oshima, Noboru Hagino, Masumi Hara, Takashi Ohfuji
Journal: Annals of Internal Medicine (2018)

Letters17 July 2018Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune DiseaseYasuo Oshima, MD, PhD, Noboru Hagino, MD, Masumi Hara, MD, PhD, and Takashi Ohfuji, MDYasuo Oshima, MD, PhDUniversity of Tokyo, Tokyo, Japan (Y.O.), Noboru Hagino, MDTeikyo University Medical Center, Chiba, Japan (N.H.), Masumi Hara, MD, PhDTeikyo University Hospital, Kanagawa, Japan (M.H.), and Takashi Ohfuji, MDKohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan (T.O.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0208 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read Abdel-Wahab and colleagues' review (1) with interest. Symptoms or diseases that clinically mimic idiopathic autoimmune diseases, known as paraneoplastic syndromes, are believed to be mediated by soluble factors or are a consequence of humoral or cellular immune mechanisms directed against tumor cells. The authors have reported flares of underlying autoimmune diseases as immune-related adverse events. We wonder whether the frequency and severity of these flares or events increased with progression of malignant tumors or destruction of malignant tumor cells.Reference1. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168:121-30. [PMID: 29297009]. doi:10.7326/M17-2073 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Tokyo, Tokyo, Japan (Y.O.)Teikyo University Medical Center, Chiba, Japan (N.H.)Teikyo University Hospital, Kanagawa, Japan (M.H.)Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan (T.O.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L18-0208. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUse of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease Noha Abdel-Wahab , Mohsin Shah , Maria A. Lopez-Olivo , and Maria E. Suarez-Almazor Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease Noha Abdel-Wahab , Mohsin Shah , Maria A. Lopez-Olivo , and Maria E. Suarez-Almazor Metrics Cited byRespiratory ComplicationsRisk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid ArthritisMultinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity 17 July 2018Volume 169, Issue 2Page: 133KeywordsAdverse eventsAutoimmune diseasesCancer treatmentCellsDisclosureMalignant tumorsPatients ePublished: 17 July 2018 Issue Published: 17 July 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...